Wie hoch ist der Preis für Scilex Holding Company (SCLX)

Preis für Scilex Holding Company (SCLX) ist $5.61

Wie hoch ist die Marktkapitalisierung für Scilex Holding Company (SCLX)

Marktkapitalisierung für Scilex Holding Company (SCLX) ist $47.65M

Scilex Holding Company (SCLX) EPS

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Jahr	EPS	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

EPS

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	EPS	EPS-Differenz	Land
Eli Lilly and Company LLY.US	$29.85	-	US
Johnson & Johnson JNJ.US	$8.65	-	US
AbbVie Inc. ABBV.US	$3.55	-	US
Roche Holding AG RO.SW	$20.39	-	CH
Merck & Co., Inc. MRK.US	$1.26	-	US

Unternehmen

EPS

EPS-Differenz

Land